Analysis of short-chain fatty acids and association with glucagon-like peptide-1 in individuals with healthy, obese, prediabetes and type 2 diabetes


Dede S., Karakuş E., Yaman M., Bilen Ö.

ACTA ENDOCRINOLOGICA, cilt.1, sa.1, ss.1-5, 2024 (SCI-Expanded)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 1 Sayı: 1
  • Basım Tarihi: 2024
  • Dergi Adı: ACTA ENDOCRINOLOGICA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1-5
  • Yıldız Teknik Üniversitesi Adresli: Evet

Özet

Context: Short-chain fatty acids (SCFAs) play a critical role in host metabolism, both directly and through specific G protein-coupled receptors, and may provide a link between glucose and lipid metabolism. This study aimed to compare fecal SCFA concentrations and to evaluate associations between SCFAs and glucagon-like peptide 1 (GLP-1) iindividuals with type 2 diabetes (T2DM), prediabetes, obesity, and health

Subject of Methods: We analyzed fecal SCFA and GLP-1 concentrations by HPLC-UV and ELISA method, respectively. 

Results: In comparison to healthy individuals, all groups exhibited notably elevated total SCFA levels (p=0.019, p=0.017, p=0.024). Acetic acid concentration showed an increase in both obese and prediabetic groups compared to the healthy group (p=0.02, p=0.017). Butyric acid concentration was elevated in T2DM and prediabetic groups in comparison to both healthy and obese groups (p=0.024, p=0.017, p=0.07, p=0.56). The GLP-1 levels significantly decreased in the obese and prediabetic groups compared to the healthy and T2DM groups (p=0.00, p=0.021, p=0.000, p=0.005). GLP-1 was correlated with acetic acid, butyric acid, and the total SCFA concentrations in the T2DM and obese groups (r= 0.479, p= 0.098; r= 0.441, p= 0.099; r= 0.654, p= 0.015, respectively) while there no any correlation in the prediabetic group.Conclusion: In general, our results extend the knowledge on the alteration of SCFA levels in the states of obesity, prediabetes, and T2DM and enrich the understanding of the relationship between SCFAs and GLP-1.